Debiopharm Honors Recipients of 2024 JCA-Mauvernay Award for Breakthrough Cancer Research
Debiopharm, a Swiss-based biopharmaceutical company focused on advancing cancer and infectious disease treatments, has announced the winners of the 2024 JCA-Mauvernay Award, celebrating its 20th edition. The award recognizes outstanding oncology research in Japan and honors two scientists: Dr. Kenichi Yoshida for Translational Research and Dr. Hiroshi Suzuki for Innovative and/or Disruptive Research. The awards were presented at the 83rd Annual Meeting of the Japanese Cancer Association (JCA) on September 21st at the Fukuoka Convention Center by Dr. Takashi Kohno, JCA Vice President.
“At Debiopharm, we are committed to fostering groundbreaking oncology research that positively impacts patient lives,” said Thierry Mauvernay, President of Debiopharm. “Our collaboration with Japanese researchers exemplifies how innovation can drive new therapies. By empowering scientists in Japan, we aim to translate discoveries into effective treatments for cancer patients worldwide, demonstrating that true innovation knows no borders.”
Dr. Kenichi Yoshida was honored for his work at the National Cancer Center Research Institute, where his research on somatic mutations in myeloid malignancies, including Myelodysplastic Syndromes (MDS), has significantly advanced understanding of these diseases. He identified new driver genes and is investigating the genetic factors behind Down Syndrome-related myeloid malignancies, as well as the carcinogenic effects of tobacco smoking on normal tissues.
Dr. Hiroshi Suzuki received the award for his innovative research on super-enhancers that influence cell identity and cancer development. His work combines next-generation sequencing, bioinformatics, and genome editing to enhance the understanding of gene dysregulation in cancer, particularly involving microRNA-140 in skeletal dysplasia. His research in CRISPR/Cas9 technology aims to improve the safety and effectiveness of genome editing.
About the JCA-Mauvernay Award
Since its inception in 2005, the JCA-Mauvernay Award has celebrated the innovative contributions of Japanese oncology researchers. With a total prize of CHF 25,000, it symbolizes the collaborative spirit between Japan and Switzerland in scientific discovery.
Over the past 20 years, the award has inspired significant advancements in oncology, including the development of second-generation ALK inhibitors for non-small cell lung cancer (NSCLC) and breakthroughs in treating adult T-cell leukemia/lymphoma (ATL) through EZH1/2 inhibitors. Additionally, the award has recognized the discovery of FGFR2 tyrosine kinase fusions, leading to the clinical development of FGFR inhibitor Tasurgratinib.
Debiopharm’s Commitment to Patients
Debiopharm is dedicated to developing innovative therapies for unmet medical needs, particularly in oncology and bacterial infections. The company focuses on identifying promising compounds, demonstrating their safety and efficacy, and partnering with large pharmaceutical companies to maximize global patient access.
